Search

Your search keyword '"Zangari M"' showing total 377 results

Search Constraints

Start Over You searched for: Author "Zangari M" Remove constraint Author: "Zangari M"
377 results on '"Zangari M"'

Search Results

6. Novel Approach to Estimate Osteoarthritis Progression: Use of the Reliable Change Index in the Evaluation of Joint Space Loss

10. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

11. BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma

22. PS1386 CARFILZOMIB AS PART OF A DOSE DENSE, LESS DOSE INTENSE TOTAL THERAPY APPROACH FOR HIGH RISK MYELOMA

23. PF606 ADVERSE IMPACT OF PRIOR THERAPY ON TRANSPLANT OUTCOME IN MULTIPLE MYELOMA

24. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma

25. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

26. Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker

27. Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma

28. Erratum: Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma

29. Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma

30. Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120)

31. Impact of bortezomib on bone health in myeloma: A review of current evidence

35. Jumping Translocations of 1q12 in Multiple Myeloma: Unexpected Intra-clonal Heterogeneity of Copy Number Aberrations in the 1q21-31 Region

36. Can we cure Multiple Myeloma by 2020? Yes

37. Inhibiting MEK in MAPK pathway-activated myeloma

38. Monoclonal gammopathy of undetermined significance: a consensus statement

39. Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)

40. Evolving indications for hematopoietic stem cell transplantation in multiple myeloma and other plasma cell disorders

42. Prevention of thalidomide and lenalidomide associated trombosis in myeloma

43. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

Catalog

Books, media, physical & digital resources